Ten start-up companies working at the interface of biomedical and data science are to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme, run by the Francis Crick Institute and funded by the medical research charity LifeArc in partnership with Cancer Research UK and UK SPINE. What will… Read More
AstraZeneca has unveiled The Discovery Centre (DISC) in Cambridge, UK – a research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists. The new £1 billion facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus… Read More
Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform. Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening. … Read More
Amcyte Pharma has launched Nasitrol nasal spray for sinus irrigation in the US. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced Covid transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of Covid-19. What… Read More
Twist Bioscience has launched Revelar Biotherapeutics to develop and commercialise an antibody that neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies. In addition, Revelar will have the ability to leverage the antibody discovery and optimisation platform of Twist Biopharma to license additional antibodies for up to five targets over the next four… Read More
Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous… Read More
The global drug discovery informatics market size is expected to reach $5.62 billion by 2028 according to a new study by Polaris Market Research. The report gives insight into current market dynamics and provides analysis on future market growth. The report is called “Drug Discovery Informatics Market Share, Size, Trends,… Read More
A group of researchers at Qatar Foundation and Hamad Medical Corporation has released a study that highlights a total of 60 disease-causing genetic variants linked with cancer, heart diseases, high cholesterol level and other diseases, with cancer-associated variants being the most frequent – which is consistent with the high prevalence… Read More
The importance of biotherapeutics as a class of drugs continues to increase. Indeed, their low toxicity and high specificity justify their investigation as drug candidates. Yet, quantification studies of biotherapies in complex biological matrices can be very challenging. In particular, high background noise and interferences due to endogenous proteins… Read More
Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise. LR: What it does Hemispherian do? ZA: We are focused on developing a novel class of small molecule drugs (GLIX)… Read More
HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC). Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both… Read More
The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents. Using a new quantitative test for drug resistance and… Read More
A novel clot-busting drug formulated and tested by University of Manchester scientists is able to effectively restore blood flow in the brains of mice, opening the door for a safer and more effective stroke treatment, according to the study published in the journal Blood. The compound, an… Read More
Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow. Dendritic cells have an important role in the… Read More
Listen to this article on the DDW Podcast: RareCan is a new company based in the UK. Its aim is to accelerate research into rare cancers. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. Professor Andy Hall, Founding Director and… Read More
Gentronix, a UK-based contract research organisation (CRO) working in the field of genetic toxicology, has raised £700,000 in a funding round led by existing investor Mercia to support its continued growth. The latest round, which includes a number of private investors, follows Gentronix’s recent acquisition of the Big Blue transgenic mutation… Read More
